The MPTP-treated mouse has proven to be a valuable model of parkinsonism. For example, C57 black mice treated with MPTP exhibit a large decrement in the neostriatal content of dopamine and its metabolites, a marked reduction in the capacity of neostriatal synaptosomal preparations to accumulate [(3H]dopamine, a large decrease in neostriatal tyrosine hydroxylase activity, a marked loss of nerve cells in the zona compacta of the substantia nigra, and pronounced behavioral deficits. These biochemical, pathological and behavioral deficits are similarly observed in MPTP-treated primates and in humans with idiopathic parkinsonism. A great deal of our current knowledge concerning MPTP has come from experimentation carried out in the mouse.
CITATION STYLE
Heikkila, R. E., & Sonsalla, P. K. (1987). The use of the MPTP-treated mouse as an animal model of parkinsonism. Canadian Journal of Neurological Sciences, 14(3 SUPPL.), 436–440. https://doi.org/10.1017/s0317167100037860
Mendeley helps you to discover research relevant for your work.